Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Par 7.5 Mg Buspirone Aims To Capture Portion of 15 Mg Split-Tablet Market

Executive Summary

Par Pharmaceutical hopes to capture a portion of the 15 mg buspirone market with the March 28 approval of its 7.5 mg strength of the anxiety drug buspirone, a generic equivalent of Bristol-Myers Squibb's BuSpar. Par has 180-day exclusivity for 7.5 mg buspirone.
Advertisement

Related Content

Par Aims To Add Branded Products After Merck KGaA Divests Equity Stake
Par Aims To Add Branded Products After Merck KGaA Divests Equity Stake
BuSpar patent appeal
Par Generic Fluoxetine Expected To Launch In Three Strengths On Aug. 2
Mylan Nebivolol Hypertension Drug Patent Protection Expected Through 2015
GPhA Waxman/Hatch Plan Would Use Bonds To Protect 180-Day Exclusivity
Mylan Buspirone Launch Awaits Bristol Appeal Of BuSpar Patent Order
Bristol BuSpar Metabolite Data Requested By FDA Before Final Patent Listing
Bristol BuSpar Metabolite Data Requested By FDA Before Final Patent Listing
Pennsylvania PACE Predicts Crisis From Medicare HMOs Dropping Rx Benefits
Advertisement
UsernamePublicRestriction

Register

PS037597

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel